Data-driven assessment of adolescents' mental health during the COVID-19 pandemic

Yonatan Bilu PhD¹, Natalie Flaks-Manov PhD¹, Maytal Bivas-Benita PhD¹, Pinchas Akiva PhD¹, Nir Kalkstein B.Sc.¹, Yoav Yehezkelli MD^{1,2}, Miri Mizrahi-Reuveni MD², Anat Ekka-Zohar PhD², Shirley Shapiro Ben David MD², Uri Lerner PhD², Gilad Bodenheimer MD² and Shira Greenfeld MD²

¹ KI Research Institute, Kfar-Malal, Israel

² Maccabi Healthcare Services, Tel-Aviv, Israel

Corresponding author:

Natalie Flaks-Manov, KI Research Institute, 11 Hazayit st, Kfar Malal, Israel.

Email: Natalie@kinstitute.org.il

Key Points

Question

Has the COVID-19 pandemic and the strategies to contain it affected adolescents' mental health?

Findings

In this retrospective cohort study of over 200,000 adolescents 12–17 years old, the incidence rates of several measured mental health diagnoses and psychiatric medications increased significantly during the COVID-19 pandemic compared to the period before. This increase was mostly attributed to females.

Meaning

This real-world study highlights the deterioration of adolescents' mental health during the COVID-19 pandemic and suggests that the mental health of this young population should be considered during management and health policy decision making.

Abstract

Importance

Adolescents' mental health and well-being were severely compromised during the COVID-19 pandemic. Longitudinal follow-up studies, based on real-world data, assessing the changes in mental health of adolescents during the later phase of the COVID-19 pandemic are needed.

Objective

To quantify the effect of COVID-19 on the incidence of Israeli adolescents' mental health outcomes from electronic health record (EHR) data.

Design, Setting and Participants

Retrospective cohort study analyzing EHR data of Maccabi Healthcare Services members, the second largest Health Maintenance Organization in Israel. Eligible subjects were 12-17 years old, during 2017-2021 with no previous diagnosis or psychiatric drug dispensation of those analyzed in this study. This resulted in over 200,000 eligible participants each year.

Exposure

COVID-19 pandemic and the measures taken to mitigate it.

Main Outcomes and Measures

Incidence rates of mental health diagnoses (depression; anxiety; obsessive-compulsive disorder; stress; eating disorders; ADHD), and psychiatric drugs dispensation (antidepressants; anxiolytics; antipsychotics; ADHD agents) were measured, and relative risks were computed between the years. Subgroup analyses were performed for age, gender, population sector and socioeconomic status. Interrupted time series (ITS) analysis evaluated changes in monthly incidence rates of psychiatric outcomes.

Results

During the COVID-19 period a 36% increase was observed in the incidence of depression (95%CI: 25-47), 31% in anxiety (95%CI: 23-39), 20% in stress (95%CI: 13-27), 50% in eating disorders (95%CI: 35-67), 25% in antidepressants (95%CI: 25-33) and 28% in antipsychotics dispensation (95%CI: 18-40). Decreased rate of 26% (95% CI: 0.80-0.88) was observed in ADHD diagnoses and 10% (95% CI: 0.86-0.93) in prescriptions of ADHD agents. The increase was mostly attributed to females in the general Israeli population; nevertheless, a 24% increase in anxiety was seen in males (95%CI: 13-37), 64% in Israeli Arabs (95%CI: 12-140) and 31% in ultra-orthodox (95%CI: 3-67). ITS analysis revealed a significantly higher growth in the incidence of psychiatric outcomes during the COVID-19 period, compared to previous years.

Conclusions and Relevance

EHR data of adolescents shows increased incidence rates of mental health diagnoses and medications during the COVID-19 pandemic, specifically identified females as those with the highest mental health burden. Our study highlights that the deteriorating mental health of children should be considered by decision-makers when actions and policies are put in place entering the third year of the pandemic.

Introduction

The COVID-19 pandemic and measures taken to control its spread have transformed the lives of adolescents, raising concern for their mental health. Although children and adolescents mostly present a milder course of COVID-19 compared to adults ^{1,2} their mental health and wellbeing were negatively impacted during the pandemic ³. Current reports have indicated that depression, anxiety and eating disorders have increased significantly since the outbreak of COVID-19 and higher prevalence rates were measured among females ^{4–6}, increasing gradually with age ⁷. However, the information regarding the increase in mental health of adolescents during COVID-19 is still limited and is not based on longitudinal follow-up of real-world data population studies. Most of the present studies are based on survey data collected during the early phase of the COVID-19 outbreak. Quantitative study designs, based on real-world data, are needed to assess the changes in mental health of children and adolescents during the COVID-19 pandemic more accurately and compare it to previous years ⁷.

The disruption caused by the pandemic was further exacerbated by the steps that were taken to mitigate it, such as three full lockdowns, social distancing policies and quarantine instructions for those exposed and infected by the SARS-CoV-2 virus. The disruption to the education system affected about 1.8 million students despite significant efforts to deploy distance learning. Previous studies have shown that whenever children are not in their educational routine, they become physically less active, their screen time is much prolonged, they have irregular sleep schedules and their diets are less healthy^{8,9}. Furthermore, pandemic stressors such as the threat of the disease, decreased peer interactions, lack of personal space at home, and family's financial loss may have even more troublesome and enduring impacts on children's mental health⁸. In this study we quantified

the effect of COVID-19 on the incidence of Israeli youth mental health outcomes based on comprehensive EHR data.

Methods

STUDY POPULATION AND DESIGN

Data in this study originated from Maccabi Healthcare Services (MHS), the second largest Health Maintenance Organization (HMO) in Israel, which includes 2.5 million insured citizens with longitudinal EHR dated back to 1993. We performed a retrospective cohort study design of adolescents, 12-17 years old (up to their 18th birthday) between November 1st, 2016, and October 31st, 2021.

OUTCOMES

We examined incidence rates of several outcomes associated with mental distress. These included five categories of mental health diagnoses: depression (ICD10 F32, F34); anxiety and obsessive-compulsive disorder disorders (ICD10 F41, F42); adjustment and emotional problems, stress-related conditions (ICD10 F43, F93; henceforth denoted as "stress"), eating disorders (ICD10 F50) and attention deficit hyperactivity disorder (ADHD) (ICD10 F90). Furthermore, we assessed four categories of drugs dispensed during those years – antidepressants (ATC code N06A), anxiolytics (ATC code N05B), antipsychotics (ATC code N05A) and psychostimulants, agents used for ADHD and nootropics (ATC code N06B; henceforth denoted as "ADHD agents"). These diagnoses and prescriptions were given by physicians of various specializations (Figure S7).

DEMOGRAPHIC VARIABLES

We examined trends in mental illness stratified by age sub-groups (12-13, 14-15, 16-17 years old), sex assigned at birth (male, female), sector (general Israeli population, Israeli-Arab, and Ultra-Orthodox Jewish) and socioeconomic status on a scale from 1 to 10 (SES;

low 1-3, medium 4-7 and high 8-10). SES and population sectors were determined by the participant's geo-statistical area of residence using *Points Location Services LTD* (POINTS), which integrates information from the Israeli Central Bureau of Statistics with other socioeconomic and demographic data sources¹⁰. The Israeli Ministry of Health and all four health maintenance organizations use the POINTS data to explore SES and sectors routinely. Individuals with missing sector information (less than 0.01%) and unlisted SES were excluded from the SES sub-analysis (1.1%) but were included in all other analyses. Sex and age were listed for all members.

STATISTICAL ANALYSIS

Incidence was computed by considering the cohort of all MHS' members 12-17 years old at the beginning of the year, who did not previously receive a diagnosis, or a medication of the type being considered. The number of members who received the measured diagnosis or medication during the year was counted and normalized by the size of the cohort. Relative Risks (RRs) per 1,000 members and associated 95% confidence intervals (CIs) and p-values were computed to measure the changes and their significance in mental illness trends between each following year and between two time periods: pre-COVID-19 (year 2019 vs 2017) and during COVID-19 (year 2021 vs 2019). Since our data extended up to Oct 31st, 2021, each analyzed year started on Nov 1st of the previous year and ended on Oct 31st. To present the results of the RRs and 95% CIs we used forest plots.

We used an interrupted time series design (ITS)¹¹ to quantify changes in the level and growth in monthly incident rates before and during the COVID-19 pandemic. The interruption was defined on Feb. 27th, 2020, the day the first case of COVID-19 was detected in Israel. We used linear regression models and included Fourier terms to model the seasonal factors, with P value <.05 considered statistically significant. Fourier analysis

resolves the time dimension variable and allows to identify, quantify, and remove the timebased cycles in the data¹². Statistical analyses were conducted using Python version 3.7.1 and the statsmodels package version 0.12.

Ethics declarations

The study protocol was approved by Maccabi Health Services' institutional review board (MH6-0006-21), and informed consent was waived. The study included retrospective, deidentified data therefore, presented minimal risk and did not adversely affect the rights and welfare of the subjects.

Results

We evaluated EHR data of 12–17 years old adolescents to assess mental health outcomes before and during the pandemic. For each outcome measured we excluded those with a history of that specific outcome, therefore, the population numbers differed between outcomes. We measured average population sizes of 200,824 in 2017, 207,703 in 2019 and 218,146 in 2021 and this population consisted of 50.4% males on average. The demographic share of the general Israeli population in this cohort was 79.8%, the community of ultra-orthodox Jews was 12.5%, and 7.7% were Israeli Arabs (Table 1). Diagnoses and medication incidence rates for mental health increased over time, however the rise was higher during the COVID-19 period than the pre-COVID-19 period. Overall, the incidence rates of depression increased by 36%, anxiety by 31%, eating disorders by 50% and stress by 20% from 2019 and 2021 (eTable 1).

First, we explored the yearly outlook of all the outcomes tested by plotting the monthly incidence rates of an outcome per 1,000 members for each year from 2017 to 2021. In the beginning of the COVID-19 pandemic (March-April 2020), we observed a drastic

decrease in the rates of all diagnoses and medications, corresponding to the first, and strictest, lockdown. However, from May 2020 rates of most diagnoses and medications increased and were high throughout 2021 compared to the years before the pandemic (Figure 1). As the year 2020 included a pre-pandemic period in the beginning of the year, followed by the COVID-19 outbreak in March, a period where access to mental health services was severely disrupted, we analyzed 2021 as the COVID-19 period and 2019 as the pre-pandemic period. To quantify the effect of the COVID-19 period on the mental health of adolescents, we compared the relative risk of incidence in the pre-COVID-19 period (2019 vs 2017) and during the COVID-19 period (2021 vs 2019) (eTable1; Figure 2). The analysis of the COVID-19 period presented a sharp rise in mental health outcomes such as 36% increase in depression (RR=1.36; 95%CI: 1.25-147), 31% in anxiety (RR=1.31; 95% CI: 1.23-1.39), 20% in stress (RR=1.20; 95% CI: 1.13-1.27), 50% in eating disorders (RR=1.50; 95% CI: 1.35-1.67), 25% in antidepressants (RR=1.25; 95% CI: 1.25-1.33) and 28% in antipsychotics (RR=1.28; 95% CI: 1.18-1.40). We found a small, albeit statistically significant, decrease in the rate of ADHD diagnoses (RR=0.84; 95% CI: 0.80-0.88) and corresponding prescriptions of ADHD agents (RR=0.90; 95% CI: 0.86-0.93).

To better describe the specific populations who demonstrated the sharpest increase in incidence of mental health outcomes, we performed additional sub-analyses. In the gender-stratified analyses, most of the increase in incidence rates of psychiatric diagnoses and medications was associated with females, while males generally presented risk rates that were not significantly different from previous years (Figure 2a). While in the pre-COVID-19 period a significant increase among females was only measured in anxiety diagnosis (RR=1.15; 95% CI: 1.04-1.26) and antidepressants dispensation (RR=1.11; 95% CI: 1.01-1.21), during the COVID-19 period we observed significant increases in incidence rates of

depression (RR=1.61; 95% CI: 1.45-1.88), anxiety (RR=1.36; 95% CI: 1.25-1.48), stress (RR=1.27; 95% CI: 1.18-1.37), eating disorders (RR=1.59; 95% CI: 1.41-1.79), antidepressants (RR=1.40; 95% CI: 1.3-1.51) and antipsychotics (RR=1.66; 95% CI: 1.47-1.80). The only significant increase measured in males during COVID-19 period was 24% in anxiety (RR=1.24; 95% CI: 1.13-1.37).

Next, we performed a narrower age stratification to evaluate whether a more specific age group was associated with the increase in psychiatric diagnoses or drug dispensation. Age-group analyses have shown a significant increase during COVID-19 period in diagnoses of depression, anxiety, stress and eating disorders among all the groups, with the highest increase observed in the age group of 14-15 years old (Figure 2b). This group presented significant increases in diagnoses of depression (RR=1.49; 95% CI: 1. 1.30 – 1.72), anxiety (RR=1.38; 95% CI: 1.23-1.54), stress (RR=1.29; 95% CI: 1.17-1.42) and eating disorders (RR=1.60; 95% CI: 1.35-1.90). Furthermore, the incidence rates of antidepressants and antipsychotics dispensation had the most pronounced increase among the same age group (RR=1.32; 95% CI: 1.20-1.46 and RR=1.38; 95% CI: 1.19-1.59 respectively).

The Israeli society is composed of different sectors that usually present considerable disparities between them, therefore we sub-analyzed the effect of the COVID-19 period on mental health outcomes of adolescents in the different sectors. The sector-stratified analyses showed that most of the increase in the incidence rates of psychiatric diagnoses and medications dispensation was associated with the general Israeli population. A single significant increase was observed in the Israeli Arab and ultra-orthodox communities in anxiety diagnosis (Figure 2c). The incidence rates of anxiety in the ultra-orthodox community increased by 31% during the pandemic period (RR=1.31; 95% CI: 1.03-1.67) and among Israeli Arabs by 64% (RR=1.64; 95% CI: 1.12-2.40).

The effect of socioeconomic status (SES) on the increased incidence in mental health outcomes in adolescents during the COVID-19 period was also examined. Sub-group analysis by socioeconomic status (Figure 2d) was done by portioning the sample into three groups, low status representing about 12% of the sample, over 60% of the sample with medium status and high status at about 25% of the sample. The medium and high SES groups presented a more distinct change, showing significant incident increases in six outcomes: depression (RR=1.45 95% CI: 1.31-1.60; RR=1.19; 95% CI: 1.02-1.40 respectively), anxiety (RR=1.32 95% CI: 1.22-1.43; RR=1.23; 95% CI: 1.08-1.39), eating disorders (RR=1.49 95% CI: 1.30-1.69; RR=1.56; 95% CI: 1.28-1.90), stress (RR=1.18 95% CI: 1.11-1.27; RR=1.21; 95% CI: 1.07-1.37), antidepressants dispensation (RR=1.28; 95% CI: 1.20-1.38; RR=1.25; 95% CI: 1.12-1.39) and antipsychotics dispensation (RR=1.29; 95% CI: 1.17-1.43; RR=1.38; 95% CI: 1.16-1.64). In the low SES group, the increase was less visible, with only two significantly increased outcomes: anxiety (RR=1.49 95% CI: 1.16-1.92) and stress (RR=1.25 95% CI: 1.03-1.52). The decrease in ADHD agents was observed across all SES groups. Notably, we observed among the high SES group a significant increase in prescription of antidepressants (RR=1.16 95% CI: 1.03-1.32), and among medium SES group a significant increase in prescription of antipsychotics (RR=1.16 95% CI: 1.03-1.30) for the pre-pandemic period.

To enable a more refined analysis examining to what extent the trends during the COVID-19 era are a continuation of past trends and to what extent they break away from them, we performed Interrupted Time Series (ITS) analysis. We evaluated six different models for this analysis which differed in the time periods used to fit the data and the number of interruption points (Figures S1-S6). We observed that following a decline in incidence rates during the first lockdown (from mid-March to the end of April 2020), there was an increase in incidence rates of all diagnoses and medications dispensation, which was

significantly higher than the trend in previous years (Figure 3). Varying the analysis by introducing a "gap" period during this first lockdown period, and optionally also during the following month, so as not to be biased by the initial sharp decline, led to qualitatively comparable results (Figures S2-S5). Introducing a second interruption point on March 7th, 2021, the day all schools were opened following an extensive vaccination campaign, resulted in a significant decline following that point in the incidence of antidepressant and anxiolytic dispensation as well as of diagnoses of anxiety, stress and eating disorder (eFigure 6 and eTable 2).

Discussion

The COVID-19 pandemic has taken a toll on the mental health and wellbeing of children and adolescents. While most recent studies used surveys to assess the status of mental health in adolescents ^{7,13}, we approached the issue from a quantitative perspective and compared new psychiatric diagnoses and drug dispensation in adolescents before and during the COVID-19 pandemic based on comprehensive EHR data. Consistent with studies showing a sharp increase in reports of mental health problems 4,7,14, we observed a significant increase in diagnoses of depression, anxiety, stress and eating disorders during the COVID-19 period compared to previous years. These observations can be attributed to a wide range of stressors that appeared during the pandemic. The increase in depression, anxiety and stress might have been a result of fear of morbidity and mortality (to self or loved ones) from the new unknown illness, excessive media exposure with alarming content, continuous changes in guidelines and restrictions which led to prolonged social isolation, loss of peer interactions and support during school closures (eTable 3), reduced extracurricular and physical activity, disruption of daily routines, decreased hope for the future and loss of pleasure in activities ^{15–17}. The introduction of new distance learning

technologies imposed new challenges involving constant self-observation through cameras and different academic success evaluation, compromising adolescents' self-esteem. When Eating disorders are associated with body dissatisfaction, poor self-esteem and depression¹⁸, an illusion of control over the body may have been more readily triggered by the uncertainty of the new reality. While the increase in psychiatric drug dispensation was mostly aligned with the corresponding diagnoses, the increase in dispensation of antipsychotic drugs was not associated with any specific diagnosis measured in this study and was particularly pronounced in females, might indicate incidences of self-harm and personality disorders¹⁹. Among the reasons for increased incidence of psychiatric outcomes, we should also consider the extended time periods adolescents spent at home with their immediate family that may have promoted enhanced parental awareness and led to increased legitimacy to discuss mental distress during these times ²⁰.

While rates of depression and anxiety increased during the COVID-19 period in this study, we observed a reduction in the rates of ADHD diagnoses and prescription medications. As reports in recent years have shown an overall rise in ADHD diagnoses and medications ^{21,22}, one explanation of our findings might be that ADHD diagnoses and medication use are seasonal, with adherence levels reported to be higher during the school year than during school vacations^{23–26}. Since the COVID-19 period was characterized by intermittent closure of schools, this observed reduction in diagnoses and drug use is in line with the seasonal decrease during a normal school year's summer break. Furthermore, lower attendance in classes reduced student numbers which may have created a better environment for those with concentration difficulties. This reality might have also increased teachers' tolerance to class absence, lack of task completion and behavioral problems, therefore less inclined to refer adolescents to ADHD evaluation. These findings may suggest

under-diagnosed and untreated ADHD in adolescents putting them at risk for more serious outcomes, such as increased rates of criminal activity, accidents as well as anxiety and depression²⁷.

The most significant finding in this study is the greater risk of adolescent females diagnosed with a variety of mental disorders for the first time during the pandemic compared to the risk observed for males. In this EHR analysis, risk for anxiety was the only significant mental outcome that was increased among males. These findings are consistent with previous studies which suggested that loneliness was associated with elevated depression symptoms in females and with elevated social anxiety in males ^{28,29}. Other studies found both increased depressive and anxiety symptoms among females^{4–7}. The World Health Organization (WHO) reported lower levels of mental health and life satisfaction among females compared to males³⁰. Gender differences in mental disorders are known and consistent in the field of psychiatry, but the reasons for these differences are still not clear enough³¹. The potential risk factors could be the influence of sex hormones, higher rates of interpersonal stressors, females' lower baseline self-esteem and higher tendency for body shame, exposure to stress associated with lack of gender equality and discrimination and higher chance of experiencing interpersonal violence^{31–33}. While this could imply that females are more sensitive to the effects of the pandemic, this can also be attributed to higher tendency of females sharing their mental distress with their parents or physicians and getting the diagnosis and treatment for their condition. The apparent lack of increase among males might be because they are more frequently referred to mental health services by their school following behavioral issues. As schools were closed intermittently during the analyzed period, potential increase due to the pandemic may have been offset by the decrease in school referrals²⁹. Importantly, mental distress among male adolescents

may manifest in ways which are not directly reported in the EHR, such as violence, dropout, and substance abuse.

Stratifying by age, our findings show that there was an increase in mental illness in all age groups, more pronounced among 14-15-year-olds. Yet, as described in previous studies⁷, we found that the incidence rates themselves, of depression, anxiety, and the associated medication, are highest among 16–17-year-olds. High rates among older adolescents may be due to changes associated with puberty, a response to the stress of lockdowns and the global pandemic, and lack of socialization with peers which is particularly important at this age. In younger children increased anxiety and depression may be more readily attributed to changes in routine^{34,35}. Comparing the sectors in the Israeli population showed that different circumstances and lifestyle during the COVID-19 period are associated with different mental health outcomes in adolescents. In the ultra-orthodox community, we observed a significant increase only in the diagnosis of anxiety (31%). Ultra-orthodox Jews, accounting for 12% of the Israeli population, form of a closely-knit religious communities, living by strict Jewish laws and tradition³⁶. In this sector, the pandemic caused tension between governmental instructions and instructions from prominent community leaders who advocated keeping schools open for holy studies ^{37,38}. Many media venues such as TV, internet, and secular newspapers are not used in this sector, potentially buffering them from the exacerbating impact of reports and discussions in these venues. Moreover, while in recent years there is a growing openness and legitimacy for the discussion of mental health in this community, utilization of mental health services is still much lower than in the general Israeli population^{37,39}. Similar to the Ultra-Orthodox sector, in the Israeli-Arab sector we observed a significant increase only in the diagnosis of anxiety (64%). This sector, which accounts for 20% of the total Israeli population, utilizes mental health services at a much

lower rate than the rest of the population, possibly due to lower access to healthcare services as many reside in peripheral areas, as well as negative cultural perception and stigma associated with mental health problems^{40,41}.

A significant increase in mental health diagnoses during the COVID-19 pandemic period was observed across different SES. Differently from previous studies reporting that children and adolescents who grow up in families with lower SES have more symptoms of anxiety and depression^{42–44}, the incidence rates of most diagnoses in this study increased with higher SES. Distinctly in Israel, the Israeli-Arab and ultra-orthodox communities are associated with lower SES³⁷ and as mentioned earlier, in these sectors the rates of diagnoses related to mental status are lower than the rest of the population for cultural, religious, and other reasons. Although lower SES is often associated with poor mental health, other mediators might affect this association. Social engagement with friends and family is linked to better mental health and affects the link between SES and mental health⁴⁵. Ultra-orthodox communities in Israel are usually of lower SES, nevertheless they are socially active environments which provide members with social and spiritual support⁴⁶. The community settings offer psychosocial engagement and continuous assistance which results in better health and mental health that would be expected based on their SES^{46,47}.

Our study has several limitations. While the findings in this study are clear and consistent with other studies, the reported incidence rates are probably an underestimation of the actual numbers. Many adolescents are diagnosed and treated by mental health professionals in private clinics outside their HMO, and such diagnoses are not recorded in their EHR. Psychiatric drugs prescribed outside the HMO are also not recorded and were not included in this analysis. Furthermore, there is a long standby time for mental health services, starting at an average of three months before an initial assessment, and several

additional months before receiving treatment⁴⁸ - so not all those who seek and need help are included in this study. Our analysis addressed these limitations by comparing the risk ratios of the outcomes, measuring the difference in new mental health diagnoses and dispensation within the HMO in different time periods.

In this study, the rates of new cases of mental health diagnoses and drug dispensation were determined in individuals that had no history of the specific measured outcome. However, mental health often presents multiple comorbidities at different times in patients' history, i.e. depression may appear before anxiety diagnosis or anti-depressants dispensation. Future studies could explore how pre-COVID mental health diagnoses and prescriptions affected new mental health outcomes during the pandemic.

Conclusions

To the best of our knowledge, this study is the first data-driven quantitative estimation of the mental health burden on adolescents during the COVID-19 pandemic. This observational cohort study showed a significant increase in mental health diagnoses and in psychiatric drugs dispensation during the COVID-19 period compared to the corresponding pre-COVID period. Our findings highlight the specific sub-populations which need to be considered when deciding on policies and promotion of adolescent resilience. These findings should warrant similar studies in other geographical areas and in other age groups. Strategies to address the deteriorating mental health of adolescents during the COVID-19 pandemic and prevent further deterioration as the disease continues to spread should be a priority.

Acknowledgments

We thank Yossi Levi, Yair Goldberg and Stephen Levine for helpful comments and discussion on the Interrupted Time Series methodology. Chen Yanover and Tal El-Hai are acknowledged for their insightful methodological suggestions and illuminating discussions.

References

- Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. *Archives of Disease in Childhood* 106, 429–439 (2021).
- Götzinger, F. et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child & Adolescent Health 4, 653–661 (2020).
- 3. Howard-Jones, A. R. *et al.* COVID-19 in children: I. Epidemiology, prevention and indirect impacts. *Journal of Paediatrics and Child Health* **n/a**,.
- Magson, N. R. et al. Risk and Protective Factors for Prospective Changes in Adolescent Mental Health during the COVID-19 Pandemic. J Youth Adolescence 50, 44–57 (2021).
- 5. Meherali, S. *et al.* Mental Health of Children and Adolescents Amidst COVID-19 and Past Pandemics: A Rapid Systematic Review. *International Journal of Environmental Research and Public Health* **18**, 3432 (2021).
- Thorisdottir, I. E. et al. Depressive symptoms, mental wellbeing, and substance use among adolescents before and during the COVID-19 pandemic in Iceland: a longitudinal, population-based study. The Lancet Psychiatry 8, 663–672 (2021).
- Racine, N. et al. Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis. *JAMA Pediatrics* (2021) doi:10.1001/jamapediatrics.2021.2482.

- 8. Brooks, S. K. *et al.* The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *The Lancet* **395**, 912–920 (2020).
- 9. Wang, G., Zhang, Y., Zhao, J., Zhang, J. & Jiang, F. Mitigate the effects of home confinement on children during the COVID-19 outbreak. *Lancet* **395**, 945–947 (2020).
- 10. Hananel, R., Fishman, R. & Malovicki-Yaffe, N. Urban diversity and epidemic resilience:

 The case of the COVID-19. *Cities* **122**, 103526 (2022).
- 11. Bernal, J. L., Cummins, S. & Gasparrini, A. Corrigendum to: Interrupted time series regression for the evaluation of public health interventions: a tutorial. *Int J Epidemiol* **50**, 1045 (2020).
- Fourier Analysis an overview | ScienceDirect Topics.
 https://www.sciencedirect.com/topics/neuroscience/fourier-analysis.
- 13. Listernick, Z. I. & Badawy, S. M. Mental Health Implications of the COVID-19 Pandemic Among Children and Adolescents: What Do We Know so Far? *PHMT* **Volume 12**, 543–549 (2021).
- 14. Cost, K. T. et al. Mostly worse, occasionally better: impact of COVID-19 pandemic on the mental health of Canadian children and adolescents. Eur Child Adolesc Psychiatry (2021) doi:10.1007/s00787-021-01744-3.
- 15. Fegert, J. M., Vitiello, B., Plener, P. L. & Clemens, V. Challenges and burden of the Coronavirus 2019 (COVID-19) pandemic for child and adolescent mental health: a narrative review to highlight clinical and research needs in the acute phase and the long return to normality. *Child Adolesc Psychiatry Ment Health* 14, 20 (2020).
- 16. Camila Saggioro de Figueiredo. COVID-19 pandemic impact on children and adolescents' mental health: Biological, environmental, and social factors. (2021).

- 17. Lee, J. Mental health effects of school closures during COVID-19. *The Lancet Child & Adolescent Health* **4**, 421 (2020).
- 18. Jebeile, H., Lister, N. B., Baur, L. A., Garnett, S. P., & Paxton, S. J. Eating disorder risk in adolescents with obesity. *Obesity Reviews* **22**, e13173 (2021).
- 19. Hawton, K. *et al.* Interventions for self-harm in children and adolescents. *Cochrane Database of Systematic Reviews* (2015) doi:10.1002/14651858.CD012013.
- 20. Rider, E. A., Ansari, E., Varrin, P. H. & Sparrow, J. Mental health and wellbeing of children and adolescents during the covid-19 pandemic. 14.
- Ponizovsky, A. M., Marom, E. & Fitoussi, I. Trends in attention deficit hyperactivity disorder drugs consumption, Israel, 2005–2012. *Pharmacoepidemiology and Drug Safety* 534–538 (2014).
- 22. Vinker, S., Vinker, R. & Elhayany, A. Prevalence of Methylphenidate Use among Israeli Children 1998–2004. *Clin. Drug Investig.* **26**, 161–167 (2006).
- 23. Cascade, E., Kalali, A. H., Weisler, R. H. & Lenderts, S. Seasonality and the Changing Adult/Child Prescription Ratios in ADHD Therapy. *Psychiatry (Edgmont)* **5**, 23–25 (2008).
- 24. Khoza, S., Oladapo, A. O. & Barner, J. C. Adherence to medication for attention deficit/hyperactivity disorder: does time frame matter? *Journal of Pharmaceutical Health Services Research* **2**, 157–163 (2011).
- 25. Shyu, Y.-C. et al. Seasonal Patterns of Medications for Treating Attention— Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine. Clinical Therapeutics 38, 595–602 (2016).
- 26. Cohen, H. A., Savitsky, B., Ashkenasi, A. & Hoshen, M. Seasonality of Methylphenidate Administration among Children in Israel. *Isr Med Assoc J* **18**, 655–660 (2016).

- 27. Issues in Diagnosis of Attention-Deficit/Hyperactivity Disorder in Adolescents James Nahlik, 2004. https://journals.sagepub.com/doi/abs/10.1177/000992280404300101.
- 28. Liu, H., Zhang, M., Yang, Q. & Yu, B. Gender differences in the influence of social isolation and loneliness on depressive symptoms in college students: a longitudinal study. *Soc Psychiatry Psychiatr Epidemiol* **55**, 251–257 (2020).
- 29. Loades, M. E. et al. Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19. Journal of the American Academy of Child & Adolescent Psychiatry 59, 1218-1239.e3 (2020).
- 30. World Health Organization. Adolescents' mental well-being. (2016).
- 31. Riecher-Rössler, A. Sex and gender differences in mental disorders. *The Lancet Psychiatry* **4**, 8–9 (2017).
- 32. Kuehner, C. Why is depression more common among women than among men? *The Lancet Psychiatry* **4**, 146–158 (2017).
- 33. Essau, C. A., Lewinsohn, P. M., Seeley, J. R. & Sasagawa, S. Gender differences in the developmental course of depression. *Journal of Affective Disorders* **127**, 185–190 (2010).
- 34. Oldehinkel, A. J., Verhulst, F. C. & Ormel, J. Mental health problems during puberty:

 Tanner stage-related differences in specific symptoms. The TRAILS study. *Journal of Adolescence* **34**, 73–85 (2011).
- 35. Hall-Lande, J. A., Eisenberg, M. E., Christenson, S. L. & Neumark-Sztainer, D. Social isolation, psychological health, and protective factors in adolescence. *Adolescence* **42**, 265–286 (2007).

- 36. Coleman-Brueckheimer, K. & Dein, S. Health Care Behaviours and Beliefs in Hasidic

 Jewish Populations: A Systematic Review of the Literature. *J Relig Health* **50**, 422–436

 (2011).
- 37. Saban, M., Myers, V., Shachar, T., Miron, O. & Wilf-Miron, R. R. Effect of Socioeconomic and Ethnic Characteristics on COVID-19 Infection: the Case of the Ultra-Orthodox and the Arab Communities in Israel. *J. Racial and Ethnic Health Disparities* (2021) doi:10.1007/s40615-021-00991-z.
- 38. Sivan, E. & Caplan, K. Israeli Haredim: integration without assimilation. (2003).
- 39. Greenberg, D. & Witztum, E. Challenges and conflicts in the delivery of mental health services to ultra-orthodox Jews. *Asian Journal of Psychiatry* **6**, 71–73 (2013).
- 40. Pinto-Foltz, M. D. & Logsdon, M. C. Stigma Towards Mental Illness: A Concept Analysis Using Postpartum Depression as an Exemplar. *Issues in Mental Health Nursing* 29, 21–36 (2008).
- 41. Chernichovsky, D. The Health of the Arab Israeli Population. 50.
- 42. Verhulst, F. & Tiemeier, H. Socioeconomic Inequalities and Mental Health Problems in Children and Adolescents. in *Mental Health and Illness of Children and Adolescents* (eds. Taylor, E., Verhulst, F., Wong, J. C. M. & Yoshida, K.) 257–274 (Springer, 2020). doi:10.1007/978-981-10-2348-4_57.
- 43. Reiss, F. Socioeconomic inequalities and mental health problems in children and adolescents: A systematic review. *Social Science & Medicine* **90**, 24–31 (2013).
- 44. Bøe, T. *et al.* Socioeconomic Status and Child Mental Health: The Role of Parental Emotional Well-Being and Parenting Practices. *Journal of Abnormal Child Psychology* **42**, 705–715 (2014).

- 45. Achdut, N. & Sarid, O. Socio-economic status, self-rated health and mental health: the mediation effect of social participation on early-late midlife and older adults. *Isr J Health Policy Res* **9**, 4 (2020).
- 46. Bart, A., and Ben-Ari, A. Personal and social adjustment to divorce in a Haredi community in Israel. *Haredi Soc. Stud. 2, 88–116.* **2**, 88–116 (2015).
- 47. Tchernichovsky, D., and Sharoni, C. The connection between social capital and health among the ultra-Orthodox. *State of the Nation Report* 383–409 (2015).
- 48. Overview of Child and Adolescent Mental Health Services in Israel » Brookdale.

 Brookdale https://brookdale.jdc.org.il/en/publication/overview-child-adolescent-mental-health-services-israel/.

Table 1: Study population characteristics, incidence rates of mental health diagnoses and medications by year a. Diagnoses

Characteristics			0	Depression		Anxiety					ng disorder			Stress	ADHD						
		Rate				Rate			Rate						Rate	Rate					
1		N		per RR year/year-1		N	N pe			N		per RR year/year-1		N		per RR year/year-1		N	N per		
Total	Year	population in	icidence :	1,000 (95% CI)	P value	population is	ncidence 1,00	0 (95% CI)	P value	population inc	idence 1,	000 (95% CI)	P value	population i	ncidence	1,000 (95% CI)	P value	population	incidence 1,000) (95% CI)	P value
Total	2017	216.121	945	4.4		209.208	1.534 7.	2		212.104	523	2.5		201,670	2,169	10.0		158,159	3.924 24.8		
1	2017	220,668	1,005	4.6 1.04 (0.95 - 1.14)	0.376	213,330	-,	7 1.05 (0.98 - 1.12)	0.193	216,109	559	2.6 1.05 (0.93 - 1.18)	0.447	201,670		10.8 1.00 (0.95 - 1.07)	0.879	159,974	.,	0.92 (0.88 - 0.96)	< 0.001
1	2019	224,552	978	4.4 0.96 (0.88 - 1.04)	0.322	216,751	-,	6 1.00 (0.93 - 1.07)	0.903	219,590	567	2.6 1.00 (0.89 - 1.12)		205,791		10.4 0.96 (0.90 - 1.02)		162,529		0.99 (0.94 - 1.03)	
1	2020	230,517	1,081	4.7 1.08 (0.99 - 1.17)	0.093	222,127		3 1.08 (1.01 - 1.16)	0.018	225,047	721	3.2 1.24 (1.11 - 1.39)		209,333		10.9 1.05 (0.99 - 1.12)		166,922		0.85 (0.81 - 0.89)	
	2021	236,291	1,398	5.9 1.26 (1.17 - 1.37)	< 0.001	227,311	2,275 10.	0 1.21 (1.14 - 1.29)	< 0.001	230,499	894	3.9 1.21 (1.10 - 1.34)	< 0.001	212,331	2,632	12.4 1.14 (1.07 - 1.20)	<0.001	172,073	3,262 19.0	0.99 (0.94 - 1.04)	0.642
Gender																					
Male	2017	74,563	219	2.9		72,386	450 6.			72,594	188	2.6		69,296	833			55,799	1,603 28.7		
1	2018 2019	75,226 75,907	222	3.0 1.00 (0.83 - 1.21) 2.8 0.96 (0.79 - 1.15)	0.962	72,962 73,494		6 1.06 (0.94 - 1.21) 8 1.03 (0.91 - 1.17)	0.341	73,162 73,804	181 181	2.5 0.96 (0.78 - 1.17) 2.5 0.99 (0.81 - 1.22)		69,227 68,944		11.8 0.99 (0.90 - 1.09) 11.2 0.95 (0.86 - 1.04)		55,881 56,567		0.92 (0.86 - 0.99) 0.92 (0.85 - 0.99)	
1	2019	78,036	230	2.9 1.05 (0.87 - 1.26)	0.669	75,369		2 1.05 (0.93 - 1.18)	0.632	75,935	223	2.9 1.20 (0.98 - 1.46)		70,082		11.1 0.99 (0.90 - 1.09)		58,521		0.88 (0.82 - 0.95)	
1	2021	81,247	338	4.2 1.41 (1.19 - 1.67)	<0.001	78,300		5 1.19 (1.06 - 1.33)	0.002	79,002		3.5 1.19 (0.99 - 1.41)		72,176		13.0 1.17 (1.06 - 1.29)		61,447		1.01 (0.94 - 1.09)	
Female	2017	71,692	300	4.2		69,327	487 7.			70,374	206	2.9		66,829	687			52,167	1,449 27.8		,
1	2018	73,843	341	4.6 1.10 (0.94 - 1.29)	0.220	71,306	558 7.	8 1.11 (0.99 - 1.26)	0.082	72,117	209	2.9 0.99 (0.82 - 1.20)	0.922	68,283	700	10.3 1.00 (0.90 - 1.11)	0.978	53,416	1,328 24.9	0.90 (0.83 - 0.96)	0.003
1	2019	75,910	317	4.2 0.90 (0.78 - 1.05)	0.197	73,264	534 7.	3 0.93 (0.83 - 1.05)	0.248	74,070	216	2.9 1.01 (0.83 - 1.22)	0.961	69,619	695	10.0 0.97 (0.88 - 1.08)	0.628	54,742	1,440 26.3	1.06 (0.98 - 1.14)	0.133
1	2020	77,165	389	5.0 1.21 (1.04 - 1.40)	0.013	74,396		1 1.11 (0.98 - 1.24)	0.089	75,200	269	3.6 1.23 (1.03 - 1.47)		70,163		11.0 1.10 (0.99 - 1.22)		55,511		0.80 (0.74 - 0.86)	
	2021	77,825	485	6.2 1.24 (1.08 - 1.41)	0.002	74,891		0 1.24 (1.12 - 1.38)	<0.001	75,807	354	4.7 1.31 (1.11 - 1.53)	0.001	69,895		12.9 1.17 (1.06 - 1.29)	0.001	56,428		1.03 (0.95 - 1.11)	0.548
Age groups 12-13 years old	2017	51,128 52,743	218 258	4.3 4.9 1.15 (0.96 - 1.37)	0.141	49,463 50,952	363 7. 407 8.	3 0 1.09 (0.94 - 1.25)	0.247	50,300 51,783	132 137	2.6 2.6 1.01 (0.79 - 1.28)	0.951	47,787 48,927	475 455	9.9 9.3 0.94 (0.82 - 1.06)	0.323	36,857 37,767	1,118 30.3	0.94 (0.87 - 1.02)	0.166
12-13 years old	2019	54,216	272	5.0 1.03 (0.86 - 1.22)	0.794	52,282		5 1.06 (0.93 - 1.22)	0.247	53,765	160	3.0 1.14 (0.91 - 1.43)		49,898	463	9.3 1.00 (0.88 - 1.14)		38,859		0.93 (0.85 - 1.01)	
1	2020	56,274	247	4.4 0.87 (0.74 - 1.04)	0.135	54,159		5 1.01 (0.88 - 1.15)	0.947	55,078	205	3.7 1.24 (1.01 - 1.52)		51,433	507	9.9 1.06 (0.94 - 1.20)		40,482		0.92 (0.84 - 1.00)	
1	2021	58,247	348	6.0 1.36 (1.16 - 1.60)	< 0.001	55,934		4 1.22 (1.08 - 1.38)	0.001	56,969	268	4.7 1.26 (1.05 - 1.52)		52,765		11.2 1.14 (1.01 - 1.28)		42,312		1.00 (0.92 - 1.09)	
14-15 years old	2017	110,989	427	3.8		107,062	749 7.			109,179	126	1.2		102,598	990	9.6		73,816	1,988 26.9		
1	2018	113,307	443	3.9 1.02 (0.89 - 1.16)		109,137		2 1.04 (0.94 - 1.14)		111,185		1.3 1.12 (0.88 - 1.43)		103,829	1,014	9.8 1.01 (0.93 - 1.10)		74,664		0.92 (0.86 - 0.98)	
	2019	115,245 118.088	417 429	3.6 0.93 (0.81 - 1.06) 3.6 1.00 (0.88 - 1.15)	0.260	110,750 113,309		5 0.90 (0.81 - 1.00)	0.042	112,863	124 150	1.1 0.85 (0.67 - 1.08)		104,505	885 971	8.5 0.87 (0.79 - 0.95)		75,835 77.803		0.99 (0.93 - 1.05)	
1	2020	120,988	447	3.7 1.02 (0.89 - 1.16)	0.973	115,801		0 1.07 (0.97 - 1.19) 1 1.16 (1.06 - 1.27)	0.172	115,454 118,174	153	1.3 1.18 (0.93 - 1.50) 1.3 1.00 (0.80 - 1.25)		106,046 107,329	991	9.2 1.08 (0.99 - 1.18) 9.2 1.01 (0.92 - 1.10)		80.338		0.82 (0.76 - 0.88)	
16-17 years old	2017	105.132	518	4.9	0.013	102,146	785 7.		0.002	102,925	397	3.9	1.000	99,072	1.179		0.830	84.343	1,936 23.0		, 0.075
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	2018	107,361	562	5.2 1.06 (0.94 - 1.20)	0.329	104,193		1 1.06 (0.96 - 1.17)	0.263	104,924	415	4.0 1.03 (0.89 - 1.18)	0.725	100,337	-,	11.9 1.00 (0.92 - 1.08)	0.984	85,310		0.92 (0.87 - 0.98)	0.014
1	2019	109,307	561	5.1 0.98 (0.87 - 1.10)	0.742	106,001		8 1.08 (0.99 - 1.19)	0.091	106,727	443	4.2 1.05 (0.92 - 1.20)		101,286		12.3 1.04 (0.96 - 1.12)		86,694		0.98 (0.92 - 1.05)	
	2020	112,429	652	5.8 1.13 (1.01 - 1.26)	0.036	108,818		6 1.09 (1.00 - 1.19)	0.055	109,593	571	5.2 1.26 (1.11 - 1.42)		103,287		12.7 1.03 (0.96 - 1.12)		89,119		0.89 (0.83 - 0.95)	
	2021	115,303	951	8.2 1.42 (1.29 - 1.57)	<0.001	111,510	1,334 12.	0 1.25 (1.15 - 1.35)	<0.001	112,325	741	6.6 1.27 (1.14 - 1.41)	<0.001	105,002	1,641	15.6 1.23 (1.14 - 1.32)	<0.001	91,735	1,758 19.2	1.04 (0.97 - 1.11)	0.307
Sector	2017	474.063	054	4.9		467.006	1.336 8.			170.742	470	2.8		150.051	1.895	11.8		123.540	3.424 27.7		
General Jewish	2017	174,062 177,600	851 900	5.1 1.04 (0.94 - 1.14)	0.458	167,906 171,070	-,	5 1.07 (0.99 - 1.15)	0.077	170,742	506	2.9 1.06 (0.93 - 1.20)	0.387	160,951 162,749	-,	12.0 1.02 (0.96 - 1.09)	0.570	124,945	.,	0.92 (0.88 - 0.97)	0.001
1	2019	180.155	876	4.9 0.96 (0.87 - 1.05)	0.392	173,174		7 1.02 (0.95 - 1.09)	0.644	176,131		2.9 1.00 (0.89 - 1.13)		163,327		11.4 0.95 (0.89 - 1.01)		126,440		0.98 (0.94 - 1.03)	
1	2020	185,019	979	5.3 1.09 (0.99 - 1.19)	0.069	177,481		3 1.08 (1.00 - 1.15)	0.038	180,607	682	3.8 1.29 (1.15 - 1.45)		166,137		12.0 1.05 (0.99 - 1.12)		130,139		0.86 (0.82 - 0.90)	
1	2021	189,689	1,305	6.9 1.30 (1.20 - 1.41)	< 0.001	181,615		2 1.21 (1.13 - 1.29)	< 0.001	185,017	832	4.5 1.19 (1.08 - 1.32)		168,472		13.7 1.15 (1.08 - 1.22)		134,397		0.96 (0.91 - 1.01)	
Ultra orthodox Jewish	2017	26,314	69	2.6		25,830	149 5.	8		25,705	36	1.4		25,562	177	6.9		20,911	386 18.5		
	2018	27,045	76	2.8 1.07 (0.77 - 1.48)	0.740	26,502		7 0.81 (0.64 - 1.03)	0.089	26,313	43	1.6 1.17 (0.75 - 1.82)		26,039	177	6.8 0.98 (0.80 - 1.21)		21,163		0.98 (0.85 - 1.13)	
1	2019	27,423	73	2.7 0.95 (0.69 - 1.31)	0.744	26,852		2 0.91 (0.70 - 1.17)	0.475	26,563	43	1.6 0.99 (0.65 - 1.51)		26,162	184	7.0 1.03 (0.84 - 1.27)		21,207		1.01 (0.87 - 1.16)	
1	2020	28,405 29,541	65 68	2.3 0.86 (0.61 - 1.20)	0.395 1.000	27,790 28.862		1 1.20 (0.93 - 1.53)	0.167	27,425 28,499	30 41	1.1 0.68 (0.42 - 1.08)		26,824 27,588	213 223	7.9 1.13 (0.93 - 1.38)		21,811 22,728		0.72 (0.62 - 0.84)	
Arab	2021	15,745	25	2.3 1.01 (0.72 - 1.41) 1.6	1.000	15,472	49 3.	6 1.10 (0.88 - 1.38) 2	0.420	15,657	17	1.4 1.32 (0.82 - 2.11) 1.1	0.285	15,157	97	8.1 1.02 (0.84 - 1.23) 6.4	U.065	13,708	114 8.3	1.28 (1.10 - 1.49)	, 0.001
	2018	16,023	29	1.8 1.14 (0.67 - 1.95)	0.684	15,758		7 1.16 (0.80 - 1.70)	0.441	15,924	10	0.6 0.58 (0.27 - 1.26)	0.181	15,378		5.0 0.78 (0.58 - 1.06)	0.111	13,866		0.72 (0.54 - 0.95)	0.022
	2019	16,974	29	1.7 0.94 (0.56 - 1.58)	0.896	16,725		6 0.70 (0.47 - 1.04)	0.074	16,896	10	0.6 0.94 (0.39 - 2.26)		16,302	88	5.4 1.08 (0.79 - 1.46)		14,882		1.16 (0.87 - 1.54)	
	2020	17,093	37	2.2 1.27 (0.78 - 2.06)	0.389	16,856		6 0.99 (0.65 - 1.51)	1.000	17,015	9	0.5 0.89 (0.36 - 2.20)		16,372		5.1 0.95 (0.70 - 1.28)		14,972		1.13 (0.87 - 1.47)	
	2021	17,061	25	1.5 0.68 (0.41 - 1.12)	0.162	16,834	71 4.	2 1.65 (1.13 - 2.41)	0.009	16,983	21	1.2 2.34 (1.07 - 5.10)	0.029	16,271	97	6.0 1.16 (0.87 - 1.56)	0.333	14,948	103 6.9	0.88 (0.68 - 1.15)	0.379
Socioeconomic status	2017	26,273	70	2.7		25,706	120 4.	7		25,881	46	1.8		25,253	174	6.9		21,351	282 13.2		
	2017	27,015	70	2.7 1.00 (0.72 - 1.39)	1.000	26,448		7 3 0.93 (0.72 - 1.20)	0.601	26,559	39	1.5 0.83 (0.54 - 1.27)	0.387	25,253	193	7.5 1.08 (0.88 - 1.33)	0.463	21,331		0.98 (0.83 - 1.15)	0.767
	2019	28,143	64	2.3 0.85 (0.61 - 1.19)	0.391	27,569		6 0.83 (0.64 - 1.09)	0.194	27,643	29	1.0 0.71 (0.44 - 1.16)		26,778	181	6.8 0.90 (0.74 - 1.11)		22,745		0.95 (0.80 - 1.12)	
	2020	28,692	77	2.7 1.18 (0.85 - 1.64)	0.354	28,099		6 1.28 (0.98 - 1.66)	0.074	28,156		0.8 0.78 (0.45 - 1.35)		27,149	227	8.4 1.24 (1.02 - 1.50)		23,122		0.80 (0.67 - 0.95)	
	2021	29,215	76	2.6 0.97 (0.71 - 1.33)	0.872	28,599	155 5.	4 1.17 (0.93 - 1.48)	0.191	28,674	37	1.3 1.58 (0.94 - 2.66)	0.093	27,398	231	8.4 1.01 (0.84 - 1.21)	0.963	23,584		1.15 (0.96 - 1.37)	0.122
Medium	2017	138,133	656	4.7		133,473	1,048 7.			135,352	342	2.5		128,074	1,516			99,492	2,520 25.3		
			672	4.8 1.01 (0.91 - 1.12)	0.891	135,291		2 1.05 (0.96 - 1.14)	0.300	137,122	383	2.8 1.11 (0.95 - 1.28)		128,781		12.0 1.02 (0.95 - 1.09)		99,946		0.90 (0.85 - 0.95)	
	2018	140,250							0.815	138.060	378	2.7 0.98 (0.85 - 1.13)	0.799	128,413	1.482	11.5 0.96 (0.89 - 1.03)	0.257	100.311		1.02 (0.96 - 1.08)	0.522
	2019	141,445	641	4.5 0.95 (0.85 - 1.05)	0.319	136,173		1 0.99 (0.91 - 1.08)					0.00*	120.042				,			
	2019 2020	141,445 144,692	750	5.2 1.14 (1.03 - 1.27)	0.012	139,033	1,239 8.	9 1.10 (1.01 - 1.19)	0.026	140,963	487	3.5 1.26 (1.10 - 1.44)		129,947	1,539	11.8 1.03 (0.96 - 1.10)	0.475	102,594	1,972 19.2	0.83 (0.78 - 0.88)	(0.001
	2019 2020 2021	141,445 144,692 147,839	750 969				1,239 8.	9 1.10 (1.01 - 1.19) 7 1.20 (1.12 - 1.30)			487			131,243	1,539 1,794		0.475	,	1,972 19.2 1,952 18.5	0.83 (0.78 - 0.88) 0.96 (0.91 - 1.03)	(0.001
High	2019 2020	141,445 144,692	750	5.2 1.14 (1.03 - 1.27) 6.6 1.26 (1.15 - 1.39)	0.012 <0.001	139,033 141,809	1,239 8. 1,522 10. 363 7.	9 1.10 (1.01 - 1.19) 7 1.20 (1.12 - 1.30)	0.026	140,963 143,872	487 585	3.5 1.26 (1.10 - 1.44) 4.1 1.18 (1.04 - 1.33)	0.008		1,539 1,794	11.8 1.03 (0.96 - 1.10) 13.7 1.15 (1.08 - 1.24) 9.9	0.475 <0.001	102,594 105,323	1,972 19.2 1,952 18.5 1,118 30.3	0.83 (0.78 - 0.88) 0.96 (0.91 - 1.03)	(0.001 0.252
	2019 2020 2021 2017	141,445 144,692 147,839 51,128	750 969 218	5.2 1.14 (1.03 - 1.27) 6.6 1.26 (1.15 - 1.39) 4.3	0.012 <0.001	139,033 141,809 49,463	1,239 8. 1,522 10. 363 7. 407 8.	9 1.10 (1.01 - 1.19) 7 1.20 (1.12 - 1.30) 3	0.026	140,963 143,872 50,300	487 585 132	3.5 1.26 (1.10 - 1.44) 4.1 1.18 (1.04 - 1.33) 2.6	0.008	131,243 47,787	1,539 1,794 475	11.8 1.03 (0.96 - 1.10) 13.7 1.15 (1.08 - 1.24)	0.475 <0.001 0.323	102,594 105,323 36,857	1,972 19.2 1,952 18.5 1,118 30.3 1,080 28.6	0.83 (0.78 - 0.88) 0.96 (0.91 - 1.03)	() <0.001 () 0.252 () 0.166
	2019 2020 2021 2017 2018	141,445 144,692 147,839 51,128 52,743	750 969 218 258	5.2 1.14 (1.03 - 1.27) 6.6 1.26 (1.15 - 1.39) 4.3 4.9 1.15 (0.96 - 1.37)	0.012 <0.001 0.141 0.794 0.135	139,033 141,809 49,463 50,952	1,239 8. 1,522 10. 363 7. 407 8. 444 8. 463 8.	9 1.10 (1.01 - 1.19) 7 1.20 (1.12 - 1.30) 3 0 1.09 (0.94 - 1.25)	0.026	140,963 143,872 50,300 51,783	487 585 132 137	3.5 1.26 (1.10 - 1.44) 4.1 1.18 (1.04 - 1.33) 2.6 2.6 1.01 (0.79 - 1.28)	0.008 0.951 0.270 0.046	131,243 47,787 48,927	1,539 1,794 475 455 463 507	11.8 1.03 (0.96 - 1.10) 13.7 1.15 (1.08 - 1.24) 9.9 9.3 0.94 (0.82 - 1.06)	0.475 <0.001 0.323 1.000 0.350	102,594 105,323 36,857 37,767	1,972 19.2 1,952 18.5 1,118 30.3 1,080 28.6 1,033 26.6 991 24.5	0.83 (0.78 - 0.88) 0.96 (0.91 - 1.03) 0.94 (0.87 - 1.02)	() <0.001 () 0.252 () 0.166 () 0.089 () 0.062

b. Medications

Characteristics		Antidepressant							tic			chotic		ADHD Agents								
				Rate						Rate					Rate					Rate		
		N	N	per	RR year/y		Domboo	N	N	per	RR year/year-1	Develop	N	N	per	RR year/year-1	Durchus	N 	N	per	RR year/year-1	Dominio
Total	Year	population	incidence	1,000	(95%	LI)	P value	population in	ncidence	1,000	(95% CI)	P value	population i	ncidence	1,000	(95% CI)	P value	population i	ncidence	1,000	(95% CI)	Pvalue
	2017	212,163	1.787	8.4				215.824	539	2.5			212,741	850	4.0			169,423	4,886	28.8		
	2018	216,569	1,943	9.0	1.07 (1.00	- 1.14)	0.054	220,652	488	2.2	0.89 (0.78 - 1.00)	0.053	216,937	877	4.0	1.01 (0.92 - 1.11)	0.810	171,754	4,734	27.6	0.96 (0.92 - 0.99)	0.025
	2019	220,245	2,054		1.04 (0.98		0.221	224,870	509		1.02 (0.90 - 1.16)		220,544	983		1.10 (1.01 - 1.21)	0.036	174,454	4,677		0.97 (0.93 - 1.01)	
	2020	225,826	2,198		1.04 (0.98		0.165	231,124	497		0.95 (0.84 - 1.07)		226,158	1,069		1.06 (0.97 - 1.16)	0.184	179,053	4,193		0.87 (0.84 - 0.91)	
	2021	231,381	2,706	11.7	1.20 (1.14	- 1.27)	<0.001	237,292	572	2.4	1.12 (0.99 - 1.26)	0.066	231,593	1,326	5.7	1.21 (1.12 - 1.31)	<0.001	184,540	4,453	24.1	1.03 (0.99 - 1.07)	0.160
Gender Male	2017	73.609	436	5.9				74.351	71	1.0			73,193	268	3.7			60.395	1.789	29.6		
Male	2017	74,281	436		1.06 (0.93	- 1.21)	0.385	75,109	74		1.03 (0.74 - 1.43)	0.868	73,193	255		0.94 (0.80 - 1.12)	0.512	60,395	1,789		0.94 (0.88 - 1.01)	0.086
	2019	74,974	537		1.14 (1.01		0.040	75,875	70		0.94 (0.68 - 1.30)		74,360	294		1.14 (0.97 - 1.35)	0.124	61.305	1.643		0.96 (0.90 - 1.03)	
	2020	76,998	557		1.01 (0.90		0.879	78,081	63		0.87 (0.62 - 1.23)		76,479	307		1.02 (0.86 - 1.19)	0.870	63,206	1,416		0.84 (0.78 - 0.90)	
	2021	80,126	676		1.17 (1.04		0.007	81,363	83		1.26 (0.91 - 1.75)		79,590	352		1.10 (0.94 - 1.28)	0.226	66,260	1,496		1.01 (0.94 - 1.08)	
Female	2017	70,412	576	8.2				71,562	158	2.2			70,550	289	4.1			56,031	1,718	30.7		
	2018	72,479	700		1.18 (1.06		0.003	73,766	127		0.78 (0.62 - 0.98)		72,521	313		1.05 (0.90 - 1.24)	0.540	57,316	1,701		0.97 (0.91 - 1.04)	
	2019	74,450	684		0.95 (0.86		0.358	76,027	128		0.98 (0.77 - 1.25)		74,508	326		1.01 (0.87 - 1.18)	0.874	58,836	1,723		0.99 (0.92 - 1.06)	
	2020	75,628 76,253	696 928		1.00 (0.90		< 0.001	77,375 78.170	143 141		1.10 (0.86 - 1.39) 0.98 (0.77 - 1.23)	0.466	75,631 76,189	347 459		1.05 (0.90 - 1.22) 1.31 (1.14 - 1.51)	< 0.001	59,850 60.644	1,448		0.83 (0.77 - 0.89) 1.09 (1.02 - 1.17)	< 0.001
Age groups	2021	50.092	461	9.2	2.32 (2.20	1.40/	-0.001	51.089	123	2.4	U.Ju (U.77 - 1.23)	0.033	50,499	195	3.9	(1.44 - 1.31)	~0.004	39,003	1,443	37.0		0.013
12-13 years old	2018	51,611	527		1.11 (0.98	- 1.26)	0.103	52,794	138		1.09 (0.85 - 1.38)	0.536	52,013	169		0.84 (0.69 - 1.03)	0.104	39,922	1,373		0.93 (0.86 - 1.00)	0.050
	2019	52,989	568		1.05 (0.93		0.430	54,309	128		0.90 (0.71 - 1.15)		53,379	208		1.20 (0.98 - 1.47)	0.080	41,085	1,375		0.97 (0.90 - 1.05)	
	2020	54,956	607	11.0	1.03 (0.92	- 1.16)	0.618	56,447	107	1.9	0.80 (0.62 - 1.04)	0.102	55,400	234	4.2	1.08 (0.90 - 1.31)	0.418	42,745	1,272	29.8	0.89 (0.82 - 0.96)	0.002
	2021	56,794	758	13.3	1.21 (1.09	- 1.34)	< 0.001	58,510	147	2.5	1.33 (1.03 - 1.70)	0.028	57,294	308	5.4	1.27 (1.07 - 1.51)	0.006	44,634	1,339	30.0	1.01 (0.93 - 1.09)	0.842
14-15 years old	2017	108,504 110,798	832 932	7.7	1.10 (1.00	1 200	0.053	110,806 113,272	241 208	2.2	0.84 (0.70 - 1.02)	0.080	107,907 109,966	498 511	4.6	1.01 (0.89 - 1.14)	0.925	81,001 82,071	2,474	30.5	0.94 (0.89 - 0.99)	0.031
	2018	112,594	957		1.01 (0.92		0.053	115,272	208		0.84 (0.70 - 1.02)		111.631	578		1.11 (0.99 - 1.26)	0.925	83,246	2,357		0.94 (0.89 - 0.99)	
	2020	115,235	935		0.95 (0.87		0.321	118,310	238		1.12 (0.93 - 1.35)		114,177	565		0.96 (0.85 - 1.07)	0.458	85,409	1.918		0.81 (0.77 - 0.86)	
	2021	118,047	1,086		1.13 (1.04		0.005	121,341	230		0.94 (0.79 - 1.13)		116,821	618		1.07 (0.95 - 1.20)	0.256	88,125	1,884		0.95 (0.89 - 1.01)	
16-17 years old	2017	103,659	955	9.2				105,018	298	2.8			104,834	352	3.4			88,422	2,412	27.3		
	2018	105,771	1,011	9.6	1.04 (0.95	- 1.13)	0.415	107,380	280	2.6	0.92 (0.78 - 1.08)	0.318	106,971	366	3.4	1.02 (0.88 - 1.18)	0.823	89,683	2,377	26.5	0.97 (0.92 - 1.03)	0.319
	2019	107,651	1,097		1.07 (0.98		0.142	109,504	302		1.06 (0.90 - 1.24)		108,913	405		1.09 (0.94 - 1.25)	0.249	91,208	2,382		0.99 (0.93 - 1.04)	0.607
	2020	110,591 113,334	1,263		1.12 (1.03		< 0.006	112,814 115,951	259 342		0.83 (0.70 - 0.98) 1.28 (1.09 - 1.51)		111,981 114,772	504 708		1.21 (1.06 - 1.38) 1.37 (1.22 - 1.54)	< 0.004	93,644 96.415	2,275		0.93 (0.88 - 0.98) 1.10 (1.04 - 1.16)	
Sector	2021	113,334	1,020	14.5	1.23 (1.10	- 1.33)	VO.001	113,331	342	2.5	1.20 (1.03 - 1.31)	0.002	114,772	700	0.2	1.37 (1.22 - 1.34)	V0.001	30,413	2,303	20.0	1.10 (1.04 - 1.10)	0.001
General Jewish	2017	170,748	1.582	9.3				173.941	461	2.7			171,296	659	3.8			133,344	4.304	32.3		
	2018	174,114	1,707	9.8	1.06 (0.99	- 1.13)	0.107	177,737	409	2.3	0.87 (0.76 - 0.99)	0.038	174,559	670	3.8	1.00 (0.90 - 1.11)	0.978	135,086	4,168	30.9	0.96 (0.92 - 1.00)	0.036
	2019	176,479	1,794		1.04 (0.97		0.285	180,585	431		1.04 (0.91 - 1.19)		176,880	748		1.10 (0.99 - 1.22)	0.070	136,686	4,064		0.96 (0.92 - 1.01)	
	2020	181,047	1,951		1.06 (0.99		0.073	185,714	413		0.93 (0.81 - 1.07)		181,497	851		1.11 (1.01 - 1.22)	0.040	140,548	3,692		0.88 (0.84 - 0.92)	
	2021	185,511	2,432		1.22 (1.15	- 1.29)	<0.001	190,761	499		1.18 (1.03 - 1.34)	0.015	185,885	1,056		1.21 (1.11 - 1.33)	< 0.001	145,076	3,870		1.02 (0.97 - 1.06)	0.499
Ultra orthodox Jewish	2017	25,818 26,549	171 206	6.6	1.17 (0.96	1.421	0.134	26,204 26,944	56 47	2.1	0.82 (0.55 - 1.20)	0.325	25,792 26,456	170 185	6.6	1.06 (0.86 - 1.31)	0.595	21,719 22,051	460 477	21.2	1.02 (0.90 - 1.16)	0.766
	2019	26,884	221		1.06 (0.88		0.560	27,339	50		1.05 (0.70 - 1.56)		26,771	214		1.14 (0.94 - 1.39)	0.191	22,142	497		1.04 (0.92 - 1.18)	
	2020	27,769	192		0.84 (0.69		0.084	28,322	68		1.31 (0.91 - 1.89)		27,654	189		0.85 (0.70 - 1.04)	0.121	22,750	382		0.75 (0.66 - 0.85)	
	2021	28,891	226		1.13 (0.93		0.220	29,464	52		0.74 (0.51 - 1.05)		28,727	237		1.21 (1.00 - 1.46)	0.058	23,697	463		1.16 (1.02 - 1.33)	
Arab	2017	15,597	34	2.2				15,679	22	1.4			15,653	21	1.3			14,360	122	8.5		
	2018	15,906	30		0.87 (0.53		0.617	15,971	32		1.43 (0.83 - 2.46)		15,922	22		1.03 (0.57 - 1.87)	1.000	14,617	89		0.72 (0.55 - 0.94)	
	2019	16,882 17,010	39 55		1.22 (0.76 1.40 (0.93		0.470	16,946 17,088	28 16		0.82 (0.50 - 1.37) 0.57 (0.31 - 1.05)	0.519	16,893 17,007	21 29		0.90 (0.49 - 1.64) 1.37 (0.78 - 2.41)	0.762	15,626 15,755	116 119		1.22 (0.93 - 1.61) 1.02 (0.79 - 1.31)	
	2020	16,979	48		0.87 (0.59		0.121	17,088	21		1.31 (0.69 - 2.52)		16,981	33		1.14 (0.69 - 1.88)	0.522	15,755	120		1.02 (0.79 - 1.31)	1.000
Socioeconomic status		20,515				2.2.5		21,000														
Low	2017	25,890	123	4.8				26,150	50	1.9			25,864	104	4.0			22,614	327	14.5		
	2018	26,669	149	5.6	1.18 (0.93	- 1.49)	0.202	26,925	55	2.0	1.07 (0.73 - 1.57)	0.770	26,563	114	4.3	1.07 (0.82 - 1.39)	0.635	23,137	357	15.4	1.07 (0.92 - 1.24)	0.397
	2019	27,785	155		1.00 (0.80		1.000	28,085	51		0.89 (0.61 - 1.30)		27,651	122		1.03 (0.80 - 1.33)	0.845	24,141	377		1.01 (0.88 - 1.17)	
	2020	28,307	138		0.87 (0.69		0.266	28,662	59		1.13 (0.78 - 1.65)		28,156	131		1.05 (0.82 - 1.35)	0.705	24,568	283		0.74 (0.63 - 0.86)	
Medium	2021	28,860 135,607	159 1,200	5.5 8.8	1.13 (0.90	- 1.42)	0.296	29,208 137,997	56 365	1.9 2.6	0.93 (0.65 - 1.34)	0.710	28,659 135,797	140 548	4.9	1.05 (0.83 - 1.33)	0.715	25,088 107,325	315 3,108	12.6 29.0	1.09 (0.93 - 1.28)	0.304
Medium	2017	137,642	1,200		1.03 (0.95	- 1.12)	0.418	140,272	294		0.79 (0.68 - 0.92)	0.003	135,797	548 592		1.07 (0.95 - 1.20)	0.286	107,325	2,988		0.95 (0.91 - 1.00)	0.063
	2019	138,738	1,328		1.05 (0.97		0.252	141,723	328		1.10 (0.94 - 1.29)	0.228	138,775	648		1.09 (0.97 - 1.21)	0.147	108,595	2,917		0.97 (0.92 - 1.02)	
	2020	141,717	1,441		1.06 (0.99		0.113	145,151	330		0.98 (0.84 - 1.14)		141,754	699		1.06 (0.95 - 1.18)	0.325	110,998	2,617		0.88 (0.83 - 0.93)	
	2021	144,750	1,778	12.3	1.21 (1.13	- 1.29)	< 0.001	148,576	369	2.5	1.09 (0.94 - 1.27)	0.256	144,661	874	6.0	1.23 (1.11 - 1.35)	<0.001	113,948	2,782	24.4	1.04 (0.98 - 1.09)	0.195
High	2017	50,092	461	9.2				51,089	123	2.4			50,499	195	3.9			39,003	1,443	37.0		
	2018	51,611	527		1.11 (0.98		0.103	52,794	138		1.09 (0.85 - 1.38)		52,013	169		0.84 (0.69 - 1.03)	0.104	39,922	1,373		0.93 (0.86 - 1.00)	0.050
	2019	52,989	568		1.05 (0.93		0.430	54,309	128		0.90 (0.71 - 1.15)		53,379	208		1.20 (0.98 - 1.47)	0.080	41,085	1,375		0.97 (0.90 - 1.05)	
	2020	54,956 56,794	607 758		1.03 (0.92		< 0.001	56,447 58,510	107 147		0.80 (0.62 - 1.04) 1.33 (1.03 - 1.70)		55,400 57,294	234 308		1.08 (0.90 - 1.31) 1.27 (1.07 - 1.51)	0.418	42,745 44,634	1,272		0.89 (0.82 - 0.96) 1.01 (0.93 - 1.09)	
	2021	56,794	/58	15.3	1.21 (1.09	- 1.34	<0.001	36,510	14/	2.5	1.33 (1.03 - 1.70)	0.028	57,294	308	5.4	1.27 (1.07 - 1.51)	0.006	44,634	1,339	30.0	1.01 (0.93 - 1.09)	0.842

Figure 1: Monthly incidence rates of mental health diagnoses and drug dispensation, comparison by years







Figure 2: Relative risks (RR) and 95% CI of incidence rates Pre COVID-19 (2019/2017 years; blue) and COVID-19 (2021/2019 years; orange): (a) partition by gender; (b) partition by age; (c) partition by sector; (d) partition by socioeconomic score.

a. Gender





c. Population Sector



d. Socioeconomic status (SES)





Figure 3: Interrupted Times Series Analysis (ITS) for mental health incidence for 5 years.



Legends: The magenta line delineates Feb. 27th, the date of the first COVID-19 case in Israel. Orange lines depict ITS models with an interruption on this date. Blue dots represent incidence rates for a 4-week period.